Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: CIPLA MEDPRO (PTY) LTD., Rosen Heights, Pasita Street, Rosen Park, Bellville, 7530. RSA
BECLATE AQUANASE (aqueous nasal spray).
| Pharmaceutical Form |
|---|
|
Nasal spray. A white homogenous, redispersable suspension. |
Each metered spray contains 50 µg beclomethasone dipropionate.
Preservatives:
Benzalkonium chloride 0,01% v/v
Phenyl ethyl alcohol 0,25% v/v.
Contains sugar (glucose 500,0 mg/10 ml)
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Beclometasone |
Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity. |
| List of Excipients |
|---|
|
Glucose (anhydrous) |
10 ml amber glass vial fitted with a metering atomising pump and nasal adaptor.
Each vial contains 7,5 ml of nasal spray (150 doses).
CIPLA MEDPRO (PTY) LTD., Rosen Heights, Pasita Street, Rosen Park, Bellville, 7530. RSA
30/21.5.1/0079
06 February 1996
| Drug | Countries | |
|---|---|---|
| BECLATE | Ecuador, Hong Kong, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
